IL41347A - Mineral salt preparation - Google Patents
Mineral salt preparationInfo
- Publication number
- IL41347A IL41347A IL41347A IL4134773A IL41347A IL 41347 A IL41347 A IL 41347A IL 41347 A IL41347 A IL 41347A IL 4134773 A IL4134773 A IL 4134773A IL 41347 A IL41347 A IL 41347A
- Authority
- IL
- Israel
- Prior art keywords
- weight
- mineral salt
- vitamin
- parts
- inclusive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Inorganic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
1356096 Mineral salt preparations F HOFFMANN-LA ROCHE & CO AG 23 Feb 1973 [25 Feb 1972] 9053/73 Heading A5B Mineral salt preparations for the replacement of minerals lost by bodily stress and increased transpiration as well as by the use of diuretics, contain in the form of salts, 1 to 16 parts by weight of calcium, 1 to 8 parts by weight of magnesium, 0.4 to 4 parts by weight of potassium and no sodium or less than 0.1 parts by weight of sodium, the calcium, potassium, magnesium and sodium constituting more than 2% by weight of the preparation. The salts may be the appropriate carbonates, phosphates, glycerophosphates, gluconates, ascorbates or D-pantothenates. The preparations may be administered orally in the form of powders, granulates, tablets (e.g. effervescent tablets), drag es, capsules, solutions, suspensions or emulsions. The preparations may also contain phosphates, vitamins, e.g. vitamin C, B 1 , B 2 , B 6 and E, nicotinic acid, nicotinamide, pantothenic acid and/or calcium D-pantothenate; sugars, e.g. glucose, lactose, fructose, saccharose, laevulose, mannitol, sorbitol or xylitol; sweetening agents; aroma additives; acid additives, e.g. citric or tartaric acid, colouring agents; solubilising agents; granulating adjuvants, preservatives; stabilisers; wetting agents; emulsifiers; salts for varying the osmotic pressure and/or buffers.
[GB1356096A]
Claims (2)
1. 41347/2
2. ) Process according to claim " 1, wherein a part of the salts, which contain calcium, magnesium, potassium and, if necessary, sodium, is phosphate and wherein the amount of phosphate used is 2 to 2 parts by weight. -3) Process according to claim .1 or claim 2, wherein vitamins and/or adjuvants are added* A) Process according to any one of claims .1 to ~ inclusive, wherein aroma additives are added. -5) Process according to any one of claims .1 to A inclusive, wherein a sweetening agent is added. 41347^2 .6) Process according to any one of claims , 1 to Γ-5 inclusive, wherein- he- mineral, salt preparation is manufactured in the form of a water-soluble granulate,, .7) Process according to any one of claims 1 to .6 inclusive, wherein a sugar is added. .8) Process according to claim 7 » wherein said sugar is fructose, saccharose , laevulose or lactose. . 9) Process according to claim .7 » wherein said sugar is sorbitol , mannitol and/or xylitol. lO), Process according to any one of claims \ to 9 inclusive , wherein salts containing a total, of 250 mg of calcium, 170 mg of magnesium, lOOmg of potassium,' 310 mg of phosphate and other anions are mixed with 500 mg of vitamin C , 10 mg of vitamin 15 m of vitamin B2 , mg of vitamin B^ , 20 mg of nicotinamide , 20 mg o f calcium D--pantothenate , 50 mg of vitamin E and adjuvants to 10, 000 mg. 11) Mineral salt preparation for the replacement of minerals lost by bodily stress and increased transpiration as well as by the use of diuretics, said preparation containing, in the form of salts, 1 to 16 parts by weight of calcium, 1 to 8 parts by weight of magnesium, 0.4- to parts by weight of potassium and no sodium or less than · 0.1 parts by weight of sodium; the weight ratio of calcium, 41^47/2 potassium, magnesium and sodium to the total weight of the preparation lying above 2%. 2 j) Mineral salt preparation according to contains 2 to 2 parts by weight of phosphate. 13) Mineral salt preparation according to clairn H or claim 22 which contains vitamins and/or adjuvants. 4 ) Mineral salt preparation according to any one of claims 11 to 15 inclusive which contains an aroma additive. 15 ) Mineral salt preparation according to any one of claims n to 14 inclusive whioh contains a sweetening agent 16 ) Mineral salt preparation according to any one of claims 11 to 15! inclusive which is present in the form of a water-soluble granulate. 17 ) Mineral salt preparation according to any one of claims 11 to 16 inclusive which contains a sugar. 18) Mineral salt preparation according to claim 17 , wherein said sugar is fructose, saccharose, laevulose or lactose. 19) Mineral salt preparation according to claim- l'7 t wherein said sugar is sorbitol, mannitol and/or xylitol. 20) Mineral salt preparation according to any one of claims H to 16 inclusive of the following compositions Vitamin C 500 mg Vitamin B1 10 mg Vitamin B2 15 mg Vitamin Bg 25 mg Nicotinamide 20 mg Clacium D-pantothenate 20 mg Vitamin E 50 mg Calcium 250 mg Magnesium 170 mg Potassium 100 mg Phosphate 310 mg together with other anions and adjuvants to 10, 000 mg. For the Applicants
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH271972 | 1972-02-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
IL41347A0 IL41347A0 (en) | 1973-03-30 |
IL41347A true IL41347A (en) | 1976-04-30 |
Family
ID=4240056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL41347A IL41347A (en) | 1972-02-25 | 1973-01-19 | Mineral salt preparation |
Country Status (14)
Country | Link |
---|---|
JP (1) | JPS4896712A (en) |
AT (1) | AT322743B (en) |
AU (1) | AU462328B2 (en) |
BE (1) | BE795827A (en) |
CA (1) | CA1023991A (en) |
DE (1) | DE2305979A1 (en) |
FR (1) | FR2173262B1 (en) |
GB (1) | GB1356096A (en) |
IE (1) | IE37291B1 (en) |
IL (1) | IL41347A (en) |
NL (1) | NL7301864A (en) |
PH (1) | PH9888A (en) |
SE (1) | SE422273B (en) |
ZA (1) | ZA73288B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI60107C (en) * | 1978-02-24 | 1982-12-13 | Suomen Laeaeketehdas Oy Salco | SOM KRYDDA ELLER SOM KONSERVERINGSMEDEL FOER LIVSMEDEL ANVAENDBAR BORDSSALTPRODUKT |
JPS579712A (en) * | 1980-06-20 | 1982-01-19 | Fukumi Morishige | Instilling (dripping) liquid for intravenous injection |
FI834309A (en) * | 1983-11-24 | 1985-05-25 | Pharmaconsult Oy | SALTBLANDNING. |
HU191598B (en) * | 1984-03-20 | 1987-03-30 | Egyt Gyogyszervegyeszeti Gyar | Method for the preparation of injection solution suitable preferably against cathosis |
US5035898A (en) * | 1987-11-27 | 1991-07-30 | Schering Corporation | Potassium/magnesium supplement |
US9974319B2 (en) | 2006-03-29 | 2018-05-22 | Purac Biochem B.V. | Partially neutralized polycarboxylic acids for acid-sanding |
-
1973
- 1973-01-15 ZA ZA730288A patent/ZA73288B/en unknown
- 1973-01-18 AU AU51227/73A patent/AU462328B2/en not_active Expired
- 1973-01-19 IL IL41347A patent/IL41347A/en unknown
- 1973-02-07 DE DE2305979A patent/DE2305979A1/en not_active Withdrawn
- 1973-02-09 NL NL7301864A patent/NL7301864A/xx unknown
- 1973-02-19 IE IE251/73A patent/IE37291B1/en unknown
- 1973-02-23 CA CA164,471A patent/CA1023991A/en not_active Expired
- 1973-02-23 FR FR7306516A patent/FR2173262B1/fr not_active Expired
- 1973-02-23 SE SE7302591A patent/SE422273B/en unknown
- 1973-02-23 GB GB905373A patent/GB1356096A/en not_active Expired
- 1973-02-23 BE BE795827D patent/BE795827A/en not_active IP Right Cessation
- 1973-02-23 JP JP48021405A patent/JPS4896712A/ja active Pending
- 1973-02-23 AT AT163173A patent/AT322743B/en not_active IP Right Cessation
- 1973-02-25 PH PH14349*A patent/PH9888A/en unknown
Also Published As
Publication number | Publication date |
---|---|
SE422273B (en) | 1982-03-01 |
ZA73288B (en) | 1973-10-31 |
AU5122773A (en) | 1974-07-18 |
AT322743B (en) | 1975-06-10 |
BE795827A (en) | 1973-08-23 |
FR2173262A1 (en) | 1973-10-05 |
CA1023991A (en) | 1978-01-10 |
IL41347A0 (en) | 1973-03-30 |
FR2173262B1 (en) | 1975-10-10 |
IE37291B1 (en) | 1977-06-22 |
PH9888A (en) | 1976-06-08 |
GB1356096A (en) | 1974-06-12 |
JPS4896712A (en) | 1973-12-10 |
DE2305979A1 (en) | 1973-08-30 |
NL7301864A (en) | 1973-08-28 |
IE37291L (en) | 1973-08-25 |
AU462328B2 (en) | 1975-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Karlish et al. | On the Mechanism of Uncoupling in Chloroplasts by Ion‐Permeability Inducing Agents | |
GB1405088A (en) | Slow release formulation | |
US2822317A (en) | Aqueous iron-ascorbic acid preparation | |
GB1503886A (en) | Nonalcoholic beverages | |
IL41347A (en) | Mineral salt preparation | |
JP2000189125A (en) | Acidic drinking liquid composition | |
GR3004440T3 (en) | ||
IE37292L (en) | Mineral salt preparation | |
GB1256968A (en) | ||
GB1344558A (en) | Method for treating diseases by coenzyme a and adenosine triphosphate and composition therefor | |
GB2308810A (en) | Composition for combatting dehydration | |
IE801914L (en) | Paracetamol compositions | |
US3777029A (en) | Chewable multivitamin tablets contain-ing aluminum nicotinate | |
GB1191246A (en) | Vitamin-containing Preparations | |
GB1165098A (en) | Improvements in the Preparation of Chlorine-Producing Bactericidal Compositions | |
ES264510A1 (en) | Improvements in or relating to pharmaceutical iron preparations | |
IE44704L (en) | ß-LACTAM ANTIBIOTIC | |
GB1268292A (en) | 2-furfurylthioinosine and derivatives thereof | |
US2480517A (en) | Fused riboflavin-amide | |
GB1234328A (en) | ||
GB883169A (en) | Dry effervescent concentrate | |
GB1273092A (en) | 2-allyloxyinosine-5'-phosphate | |
IE38113L (en) | Anti-smoking preparations | |
IE38383L (en) | Doxycycline parenteral composition | |
JPH02240025A (en) | Stable aqueous solution of complex vitamin |